Estimating missing heritability for disease from genome-wide association studies.

Queensland Institute of Medical Research, 300 Herston Road, Herston, Queensland 4006, Australia.
The American Journal of Human Genetics (Impact Factor: 11.2). 03/2011; 88(3):294-305. DOI: 10.1016/j.ajhg.2011.02.002
Source: PubMed

ABSTRACT Genome-wide association studies are designed to discover SNPs that are associated with a complex trait. Employing strict significance thresholds when testing individual SNPs avoids false positives at the expense of increasing false negatives. Recently, we developed a method for quantitative traits that estimates the variation accounted for when fitting all SNPs simultaneously. Here we develop this method further for case-control studies. We use a linear mixed model for analysis of binary traits and transform the estimates to a liability scale by adjusting both for scale and for ascertainment of the case samples. We show by theory and simulation that the method is unbiased. We apply the method to data from the Wellcome Trust Case Control Consortium and show that a substantial proportion of variation in liability for Crohn disease, bipolar disorder, and type I diabetes is tagged by common SNPs.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Common cancers have been demarcated into 'hereditary' or 'sporadic' ('non-hereditary') types historically. Such distinctions initially arose from work identifying rare, highly penetrant germline mutations causing 'heredi-tary' cancer. While rare mutations are important in particular families, most cases in the general population are 'sporadic'. Twin studies have suggested that many 'sporadic' cancers show little or no heritability. To quantify the role of germline mutations in cancer susceptibility, we applied a method for estimating the importance of common genetic variants (array heritability, h 2 g) to twelve cancer types. The following cancers showed a signifi-cant (P < 0.05) array heritability: melanoma USA set h 2 g 5 0.19 (95% CI 5 0.01 –0.37) and Australian set h 2 g 5 0.30 (0.10– 0.50); pancreatic h 2 g 5 0.18 (0.06– 0.30); prostate h 2 g 5 0.81 (0.32–1); kidney h 2 g 5 0.18 (0.04 –0.32); ovarian h 2 g 5 0.30 (0.18 – 0.42); esophageal adenocarcinoma h 2 g 5 0.24 (0.14 – 0.34); esophageal squamous cell carcin-oma h 2 g 5 0.19 (0.07 – 0.31); endometrial UK set h 2 g 5 0.23 (0.01 –0.45) and Australian set h 2 g 5 0.39 (0.02 – 0.76). Three cancers showed a positive but non-significant effect: breast h 2 g 5 0.13 (0 – 0.56); gastric h 2 g 5 0.11 (0 – 0.27); lung h 2 g 5 0.10 (0 – 0.24). One cancer showed a small effect: bladder h 2 g 5 0.01 (0 –0.11). Among these can-cers, previous twin studies were only able to show heritability for prostate and breast cancer, but we can now make much stronger statements for several common cancers which emphasize the important role of genetic var-iants in cancer susceptibility. We have demonstrated that several 'sporadic' cancers have a significant inherited component. Larger genome-wide association studies in these cancers will continue to find more loci, which explain part of the remaining polygenic component. INTRODUCTION
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We performed a multistage genome-wide association study including 7,683 individuals with pancreatic cancer and 14,397 controls of European descent. Four new loci reached genome-wide significance: rs6971499 at 7q32.3 (LINC-PINT, per-allele odds ratio (OR) = 0.79, 95% confidence interval (CI) 0.74-0.84, P = 3.0 × 10(-12)), rs7190458 at 16q23.1 (BCAR1/CTRB1/CTRB2, OR = 1.46, 95% CI 1.30-1.65, P = 1.1 × 10(-10)), rs9581943 at 13q12.2 (PDX1, OR = 1.15, 95% CI 1.10-1.20, P = 2.4 × 10(-9)) and rs16986825 at 22q12.1 (ZNRF3, OR = 1.18, 95% CI 1.12-1.25, P = 1.2 × 10(-8)). We identified an independent signal in exon 2 of TERT at the established region 5p15.33 (rs2736098, OR = 0.80, 95% CI 0.76-0.85, P = 9.8 × 10(-14)). We also identified a locus at 8q24.21 (rs1561927, P = 1.3 × 10(-7)) that approached genome-wide significance located 455 kb telomeric of PVT1. Our study identified multiple new susceptibility alleles for pancreatic cancer that are worthy of follow-up studies.
    Nature genetics. 08/2014;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Maternal-fetal genotype incompatibility (MFGI) is increasingly reported to influence human diseases, especially pregnancy-related complications. In practice, it is challenging to identify the ideal incompatibility model for analysis, since the true MFGI mechanism is generally unknown. The underlying MFGI mechanism for different genetic variants can vary, and to use a single incompatibility model for all circumstances would cause power loss in testing MFGI.
    BMC genetics. 06/2014; 15(1):66.

Full-text (2 Sources)

Available from
May 22, 2014